Search Results - "Palla, R."

Diagnosis and classification of congenital fibrinogen disorders: communication from the SSC of the ISTH by Casini, A., Undas, A., Palla, R., Thachil, J., Moerloose, P.

Get full text

Inhibition of prostaglandin-degrading enzyme 15-PGDH rejuvenates aged muscle mass and strength by Palla, A R, Ravichandran, M, Wang, Y X, Alexandrova, L, Yang, A V, Kraft, P, Holbrook, C A, Schürch, C M, Ho, A T V, Blau, H M

“…Treatments are lacking for sarcopenia, a debilitating age-related skeletal muscle wasting syndrome. We identifed increased amounts of 15-hydroxyprostaglandin…”
Get full text

Prostaglandin E2 is essential for efficacious skeletal muscle stem-cell function, augmenting regeneration and strength by Ho, Andrew T. V., Palla, Adelaida R., Blake, Matthew R., Yucel, Nora D., Wang, Yu Xin, Magnusson, Klas E. G., Holbrook, Colin A., Kraft, Peggy E., Delp, Scott L., Blau, Helen M.

“…Skeletal muscles harbor quiescent muscle-specific stem cells (MuSCs) capable of tissue regeneration throughout life. Muscle injury precipitates a complex…”
Get full text

Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders by PEYVANDI, F., PALLA, R., MENEGATTI, M., SIBONI, S. M., HALIMEH, S., FAESER, B., PERGANTOU, H., PLATOKOUKI, H., GIANGRANDE, P., PEERLINCK, K., CELKAN, T., OZDEMIR, N., BIDLINGMAIER, C., INGERSLEV, J., GIANSILY‐BLAIZOT, M., SCHVED, J. F., GILMORE, R., GADISSEUR, A., BENEDIK‐DOLNIČAR, M., KITANOVSKI, L., MIKOVIC, D., MUSALLAM, K. M., ROSENDAAL, F. R.

“…Background:  The European Network of Rare Bleeding Disorders (EN‐RBD) was established to bridge the gap between knowledge and practise in the care of patients…”
Get full text

High strength sustainable concrete using silica nanoparticles by Palla, R., Karade, S.R., Mishra, G., Sharma, U., Singh, L.P.

“…•SNPs accelerate the hydration process and shorten the dormant period.•With the incorporation SNPs, initial and final setting is decreased…”
Get full text

Primary cilia on muscle stem cells are critical to maintain regenerative capacity and are lost during aging by Palla, Adelaida R., Hilgendorf, Keren I., Yang, Ann V., Kerr, Jaclyn P., Hinken, Aaron C., Demeter, Janos, Kraft, Peggy, Mooney, Nancie A., Yucel, Nora, Burns, David M., Wang, Yu Xin, Jackson, Peter K., Blau, Helen M.

“…During aging, the regenerative capacity of muscle stem cells (MuSCs) decreases, diminishing the ability of muscle to repair following injury. We found that the…”
Get full text

Autoimmune Hemolytic Anemia as a Complication of Nivolumab Therapy by Palla, Amruth R., Kennedy, Devin, Mosharraf, Hossain, Doll, Donald

“…Recently, immunotherapeutic drugs, including PD-1 inhibitors (nivolumab, pembrolizumab), PD-L1 inhibitors (atezolizumab, avelumab), and CTLA4 inhibitors…”
Get full text

SIPPET: methodology, analysis and generalizability by Peyvandi, F., Mannucci, P. M., Palla, R., Rosendaal, F. R.

“…The development of anti‐FVIII neutralizing alloantibodies (inhibitors), occurring in about one‐third of previously untreated patients (PUPs) with severe…”
Get full text

Minimal factor XIII activity level to prevent major spontaneous bleeds: reply by Menegatti, M., Palla, R., Bucciarelli, P., Peyvandi, F.

Get full text

Timing and severity of inhibitor development in recombinant versus plasma‐derived factor VIII concentrates: a SIPPET analysis by Peyvandi, F., Cannavò, A., Garagiola, I., Palla, R., Mannucci, P. M., Rosendaal, F. R., El‐Beshlawy, A., Elalfy, M., Ramanan, V., Eshghi, P., Hanagavadi, S., Varadarajan, R., Karimi, M., Manglani, M. V., Ross, C., Young, G., Seth, T., Apte, S., Nayak, D. M., Santagostino, E., Elisa Mancuso, M., Sandoval Gonzalez, A. C., Mahlangu, J. N., Bonanad Boix, S., Cerqueira, M., Ewing, N. P., Male, C., Owaidah, T., Soto Arellano, V., Kobrinsky, N. L., Majumdar, S., Perez Garrido, R., Sachdeva, A., Simpson, M., Thomas, M., Zanon, E., Antmen, B., Kavakl, K., Manco‐Johnson, M. J., Martinez, M., Marzouka, E., Mazzucconi, M. G., Neme, D., Palomo Bravo, A., Paredes Aguilera, R., Prezotti, A., Schmitt, K., Wicklund, B. M., Zulfikar, B.

“…Essentials Recombinant factor VIII (rFVIII) was contrasted with plasma‐derived FVIII (pdFVIII). In previously untreated patients with hemophilia A, rFVIII led…”
Get full text

ADAMTS‐13 assays in thrombotic thrombocytopenic purpura by PEYVANDI, F., PALLA, R., LOTTA, L. A., MACKIE, I., SCULLY, M. A., MACHIN, S. J.

“…ADAMTS‐13, the thirteenth member of the ADAMTS (A Disintegrin And Metalloprotease with Thrombo‐Spondin 1 repeats) family, is the plasma metalloprotease…”
Get full text

Lombardy diagnostic and therapeutic network of thrombotic microangiopathy by Mancini, I, Agosti, P, Boscarino, M, Ferrari, B, Artoni, A, Palla, R, Spreafico, M, Crovetti, G, Volpato, E, Rossini, S, Novelli, C, Gattillo, S, Barcella, L, Salmoiraghi, M, Falanga, A, Peyvandi, F, Peyvandi, Flora, Artoni, Andrea, Ferrari, Barbara, Palla, Roberta, Mancini, Ilaria, Agosti, Pasquale, Spreafico, Marta, Crovetti, Giovanni, Volpato, Elisabetta, Rossini, Silvano, Falanga, Anna, Russo, Laura, Barcella, Luca, Gattillo, Salvatore, Novelli, Chiara, Capuzzo, Enrico, D'Agostino, Marco, Moreno, Porcari, Alessandro, Inzoli, Ambrogio, Pagani

“…Abstract Background Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening thrombotic microangiopathy (TMA) requiring urgent treatment…”
Get full text

Reformulating the Situation Calculus and the Event Calculus in the General Theory of Stable Models and in Answer Set Programming by Lee, J., Palla, R.

“…Circumscription and logic programs under the stable model semantics are two well-known nonmonotonic formalisms. The former has served as a basis of classical…”
Get full text

ADAMTS‐13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura by BETTONI, G., PALLA, R., VALSECCHI, C., CONSONNI, D., LOTTA, L. A., TRISOLINI, S. M., MANCINI, I., MUSALLAM, K. M., ROSENDAAL, F. R., PEYVANDI, F.

“…Background:  Thrombotic thrombocytopenic purpura (TTP) is a rare life‐threatening disease. Of surviving patients, 45% develops an exacerbation or a late…”
Get full text

Minimal factor XIII activity level to prevent major spontaneous bleeds by Menegatti, M., Palla, R., Boscarino, M., Bucciarelli, P., Muszbek, L., Katona, E., Makris, M., Peyvandi, F., Halimeh, S., Lachmann, B., Bidlingmaier, C., Platokouki, H., Pergantou, H., Siboni, S. M., Schutgens, R. E. G., Borhany, M., Fatima, N., Mikovic, D., Saracevic, M., Moerloose, P., Casini, A., Ozdemir, N., Ay, Y., Mumford, A., Harvey, A., Payne, J., Shapiro, A. D., Williamson, A., Chapin, J., Hsu, F.

“…Essentials A strong association between bleeding severity and FXIII activity level (FXIII:C) was shown. The range 5–30 IU dL−1 of FXIII:C was associated with a…”
Get full text

Reprogramming activity of NANOGP8, a NANOG family member widely expressed in cancer by Palla, A R, Piazzolla, D, Abad, M, Li, H, Dominguez, O, Schonthaler, H B, Wagner, E F, Serrano, M

“…NANOG is a key transcription factor for pluripotency in embryonic stem cells. The analysis of NANOG in human cells is confounded by the presence of multiple…”
Get full text

The pluripotency factor NANOG promotes the formation of squamous cell carcinomas by Palla, Adelaida R., Piazzolla, Daniela, Alcazar, Noelia, Cañamero, Marta, Graña, Osvaldo, Gómez-López, Gonzalo, Dominguez, Orlando, Dueñas, Marta, Paramio, Jesús M., Serrano, Manuel

“…NANOG is a key pluripotency factor in embryonic stem cells that is frequently expressed in squamous cell carcinomas (SCCs). However, a direct link between…”
Get full text

Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study by Panichi, Vincenzo, Rizza, Giovanni M., Paoletti, Sabrina, Bigazzi, Roberto, Aloisi, Mauro, Barsotti, Giuliano, Rindi, Paolo, Donati, Giacli', Antonelli, Alessandro, Panicucci, Erica, Tripepi, Gianni, Tetta, Ciro, Palla, Roberto

“…Background. The ‘RISchio CArdiovascolare nei pazienti afferenti all’ Area Vasta In Dialisi' (RISCAVID) study is an observational and prospective trial…”
Get full text

Potential misdiagnosis of dysfibrinogenaemia: Data from multicentre studies amongst UK NEQAS and PRO‐RBDD project laboratories by Jennings, I., Kitchen, S., Menegatti, M., Palla, R., Walker, I., Peyvandi, F., Makris, M.

“…Introduction Mutations in fibrinogen (Fgn) genes, causing dysfibrinogenaemia, can result in either a bleeding or thrombophilic diathesis. Dysfibrinogenaemia is…”
Get full text

Lineage-restricted function of the pluripotency factor NANOG in stratified epithelia by Piazzolla, Daniela, Palla, Adelaida R., Pantoja, Cristina, Cañamero, Marta, de Castro, Ignacio Perez, Ortega, Sagrario, Gómez-López, Gonzalo, Dominguez, Orlando, Megías, Diego, Roncador, Giovanna, Luque-Garcia, Jose L., Fernandez-Tresguerres, Beatriz, Fernandez, Agustin F., Fraga, Mario F., Rodriguez-Justo, Manuel, Manzanares, Miguel, Sánchez-Carbayo, Marta, García-Pedrero, Juana María, Rodrigo, Juan P., Malumbres, Marcos, Serrano, Manuel

“…NANOG is a pluripotency transcription factor in embryonic stem cells; however, its role in adult tissues remains largely unexplored. Here we show that mouse…”
Get full text